Background:Vascular thrombosis represents a common manifestation, and complication in patient with myeloproliferative neoplasm (MPN). It is also associated with higher risk of morbidity and mortality. The acquired point mutation in Janus Associated Kinase II (JAKIIV617F) in these disorders is associated with higher incidence of thrombosis compared to patient devoid of this mutation.
Objective: This study aimed to evaluate the incidence of thrombosis, and its relation to JAK II (V617F) mutation among Egyptian MPN patients
Patients and Method: In this, study 102 patients (49 males and 53 females) at the Outpatient Clinic of Mansoura Oncology Center has been evaluated for the presence and type of thrombosis. In addition, its relation to JAKII mutation.
Results: From the 102-studied patients, 47 (46.15%) had Polycythemia Vera (PV), 27(26.5%) had essential thrombocytosis (ET), 22 (21.6%) had myelofibrosis (MF), and 6 (5.9%) patients had unclassified MPN. Vascular thrombosis has been observed in 34 (33.3%) patients, 28 (27.5%) of them at the time of diagnosis, 6 (5.9%) patients at follow up and 4 (3.9%) were having recurrent thrombosis. According to the pattern of thrombosis, 16 patients had arterial thrombosis, 14 had venous, and 4 patients had combined arterio-venous thrombosis. The association of of JAK II V617F mutation and thrombosis were statistically significant (P = 0.0003).
Conclusion: The presence of JAKII V617F mutation is associated with higher incidence of vascular thrombosis in MPN patients compared to those without this mutation.